Background Non-vitamin K antagonist oral anticoagulants (NOACs) are used to treat acute
pulmonary embolism (PE). However, lower NOAC doses are often prescribed because of …

Limited information exists on the safety and efficacy of non-vitamin K oral anticoagulants
(NOACs) in patients with pulmonary embolism (PE). The aim of this study is to evaluate the …

Introduction: Acute pulmonary embolism (PE) is a relatively common cardiopulmonary
emergency that is a major cause of hospitalization and morbidity and is the primary cause of …

Dose adjustment of direct oral anticoagulants (DOACs) is not required in the setting of acute
PE treatment according to the manufacturer's labelling, beyond the contraindication in …

Introduction: In the past decade, direct oral anticoagulants (DOACs) have been incorporated
as an anticoagulation tool in patients with acute pulmonary thromboembolism (PTE) …

The clinical management of patients with acute pulmonary embolism is rapidly changing
over the years. The widening spectrum of clinical management strategies for these patients …

The new oral anticoagulants (NOACs) have radically changed the approach to the treatment
and prevention of thromboembolic pulmonary embolism. The authors of this position paper …

Introduction Availability of new treatment strategies for patients with acute pulmonary
embolism (PE) have changed clinical practice with potential influence in short-term patients' …

Background Real-world data on the impact of advances in risk-adjusted management on the
outcome of patients with pulmonary embolism (PE) are limited. Methods To investigate …

Introduction Intermediate-high risk pulmonary embolism (IHR-PE) has a poor prognosis, but
is under-represented in trials of direct oral anticoagulants (DOACs) in venous …